Author | Kevin Kunzmann

Investigators observed stark contrasts in COVID-19 mRNA vaccination response among inflammatory rheumatic disease patients and the general population.

The indication granted Monday makes the 2-dose vaccine the very first approved by the FDA for the prescribed prevention of COVID-19.

Investigators observed that patients treated with secukinumab were more likely to achieve Psoriasis Area Severity Index (PASI) 75/90/100 responses and Investigator’s Global Assessment (IGA) improvement at 52 weeks than those administered usetkinumab, regardless of their psoriatic arthritis (PsA) status.